Status: Recruiting
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved survival outcomes.
Participants needed: 73
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Guo XufengUpdated: Sep 28, 2023Locations: 1
Eligibility criteria
The patient volunteers to participate in the study, signs a consent form, has go... [+12]
Unresectable factors, including those who are unresectable for tumor reasons or... [+13]